Log In
Print
BCIQ
Print
Print this Print this
 

Seviprotimut-L (POL-103A) (formerly POL 103A)

  Manage Alerts
Collapse Summary General Information
Company CK Life Sciences International Inc.
DescriptionMelanoma vaccine comprising a combination of purified antigens shed from 3 melanoma cell lines
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationMelanoma
Indication DetailsTreat melanoma
Regulatory Designation

U.S. - Special Protocol Assessment (Treat melanoma)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today